Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 4, 2016
Zacks Investment Research has upgraded Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) to Hold in a statement released on 10/4/2016.
On 08/05/2016, Jefferies & Co released a statement on Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) upped the target price from $7.00 to $9.00 that suggested an upside of 0.06%.
Having a price of $14.52, Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) traded 8.68% higher on the day. With the last close up 60.80% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Aquinox Pharmaceuticals Inc has recorded a 50-day average of $11.93 and a two hundred day average of $9.03. Volume of trade was up over the average, with 454,533 shares of AQXP changing hands over the typical 280,841
With a total market value of $0, Aquinox Pharmaceuticals Inc has with a one year low of $6.01 and a one year high of $16.75 .
A total of 5 analysts have released a report on Aquinox Pharmaceuticals Inc. Three analysts rating the company a strong buy, one analyst rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $19.80.
More About Aquinox Pharmaceuticals Inc (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company's product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.